Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Enveric Biosciences's profit margin for the twelve months ending Sep 30, 2020 was -5.1%. For fiscal 2019 it was -6.0%, against -39.3% the year before. The highest annual figure on record is -4.0% in fiscal 2015.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -6.0% | +33.3 |
| FY2018 | Dec 31, 2018 | -39.3% | −20.6 |
| FY2017 | Dec 31, 2017 | -18.7% | −11.0 |
| FY2016 | Dec 31, 2016 | -7.7% | −3.7 |
| FY2015 | Dec 31, 2015 | -4.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -6.7% | −7.1 |
| Q2 FY2020 | Jun 30, 2020 | -9.9% | +1.5 |
| Q1 FY2020 | Mar 31, 2020 | -11.4% | +6.0 |
| Q4 FY2019 | Dec 31, 2019 | 7.3% | +199.5 |
| Q3 FY2019 | Sep 30, 2019 | 0.5% | −53.4 |
| Q2 FY2019 | Jun 30, 2019 | -11.4% | −0.0 |
| Q1 FY2019 | Mar 31, 2019 | -17.4% | −3.2 |
| Q4 FY2018 | Dec 31, 2018 | -192.2% | −183.4 |
| Q3 FY2018 | Sep 30, 2018 | 53.9% | +86.4 |
| Q2 FY2018 | Jun 30, 2018 | -11.4% | +15.4 |
| Q1 FY2018 | Mar 31, 2018 | -14.2% | −8.4 |
| Q4 FY2017 | Dec 31, 2017 | -8.8% | −19.3 |
| Q3 FY2017 | Sep 30, 2017 | -32.5% | −14.8 |
| Q2 FY2017 | Jun 30, 2017 | -26.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -5.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 10.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -17.7% | – |
See a number that looks wrong?